Objective: To report a case of ciprofloxacin-induced syndrome of inappropriate antidiuretic hormone (SIADH). Case Summary: A 68-year-old Caucasian woman presented on 2 separate occasions with generalized weakness. Both times, she was started on ciprofloxacin for a urinary tract infection. Prior to the first episode, she had also been on Augmentin for several days. On both occasions, her ciprofloxacin was discontinued on admission, and her sodium levels rose. On the first occasion, she was given 5% dextrose in water to slow the rate of rise, yet she still corrected faster than the recommended rate. After the second admission, she was briefly given hypertonic saline but remained off intravenous fluids, and her sodium again rose faster than the recommended rate. Discussion: An objective causality assessment using the Naranjo scale was done. A score of 8 revealed a probable causality between ciprofloxacin and SIADH. The likely mechanism of this reaction is ciprofloxacin crossing the blood-brain barrier and stimulating the γ-aminobutyric acid and N-methyl-D-aspartate receptors, which leads to the synthesis and release of antidiuretic hormone. Conclusion: Fluoroquinolones have the potential to cause SIADH. In this case, ciprofloxacin probably caused SIADH.
NielsenSChouCLMarplesDChristensenEIKishoreBKKnepperMA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A. 1995;92:1013-1017.
2.
CzaczkesJWKleemanCRKoenigMBostonR. Physiologic studies of antidiuretic hormone by its direct measurement in human plasma. J Clin Invest. 1964;43:1625-1640.
3.
BaumannGDingmanJF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest, 1976;57:1109-1116. doi:10.1172/JCI108377.
4.
BaylisPH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol. 2003;35:1495-1499.
5.
HannonMJThompsonCJ. The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. Eur J Endocrinol. 2010;162(suppl 1):S5-S12. doi:10.1530/EJE-09-1063.
6.
KuglerJPHusteadT. Hyponatremia and hypernatremia in the elderly. Am Fam Physician. 2000;61:3623-3630.
BallP. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother. 2003;51(suppl 1):21-27. doi:10.1093/jac/dkg209.
9.
YamFKEralySA. Syndrome of inappropriate antidiuretic hormone associated with moxifloxacin. Am J Health Syst Pharm. 2012;69:217-220. doi:10.2146/ajhp110201.
10.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
MussigKSchnauderGMorikeK. Severe and symptomatic hyponatraemia after moxifloxacin intake. Neth J Med. 2009;67:197.
13.
JaehdeULangemeijerMWde BoerAGBreimerDD. Cerebrospinal fluid transport and disposition of the quinolones ciprofloxacin and pefloxacin in rats. J Pharmacol Exp Ther. 1992;263:1140-1146.
14.
SchmuckGSchurmannASchluterG. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother. 1998;42:1831-1836.
15.
MorrisJFChristianHMaDWangH. Dendritic secretion of peptides from hypothalamic magnocellular neurosecretory neurones: a local dynamic control system and its functions. Exp Physiol. 2000;85(spec no.):131S-138S.
